Sirexatamab
Colorectal Adenocarcinoma
Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
Leap Therapeutics, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05480306CT.gov Phase 2 Study of DKN-01 in Colorectal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sirexatamab (this asset) | Leap Therapeutics, Inc. | P2 | CCC · 54 |
| Regorafenib | City of Hope Medical Center | P2 | BB |
| Trifluridine | Centre Hospitalier Universitaire Dijon | P3 | BB |
| Balstilimab | City of Hope Medical Center | P2 | BB |
| Botensilimab | City of Hope Medical Center | P2 | BB |
| Fluorouracilum | Centre Hospitalier Universitaire Dijon | P3 | BB |
| Tipiracil | Academic and Community Cancer Research United | P2 | BB |
| Oxaliplatin | Pfizer | P3 | BB |
| Cetuximab | Bayer | P2 | BB |
+42 more in the Colorectal Adenocarcinoma cohort
Other indications for Sirexatamab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Uterine Cancer | — | P2 | B · 57 |
| Carcinosarcoma | — | P2 | B · 57 |
| Metastatic Malignant Neoplasm In The Colon | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Sirexatamab in Colorectal Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/sirexatamab-colorectal-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →